insights_auto
Why is GRAL down 10.90%?
Dive Deeperchevron_right
GRAL:NASDAQ
Grail Inc
$137.28
arrow_downward
-10.90%(-16.80) 1D
$138.60
arrow_upward
+0.96% (+1.32)bedtimeAfter hours
Closed: Oct 6, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRAL...
Open
$159.43
High
$166.48
Low
$135.80
Mkt. cap
5.70B
Avg. vol.
1.18M
Volume
2.04M
52-wk high
$166.48
52-wk low
$41.50
EPS
-$9.75
Shares outstanding
44.67M
No. of employees
910
Open
$159.43
High
$166.48
Low
$135.80
Mkt. cap
5.70B
Avg. vol.
1.18M
Volume
2.04M
52-wk high
$166.48
52-wk low
$41.50
EPS
-$9.75
Shares outstanding
44.67M
No. of employees
910
News stories
From web sources and news partners
CNBC
·
11 minutes ago
This buzzy biotech stock is up 60% this year. Cramer's advice on building a stake
TipRanks
·
4 hours ago
Insider Sales Trigger Sudden Slide in GRAIL Stock
Kalkine Media
·
21 hours ago
GRAIL Inc. Officer Andrew Partridge Files Form 144 to Sell 7,873 Shares for RSU Tax Withholding
Stock Titan
·
23 hours ago
An officer sold 7,873 shares to cover vesting taxes at GRAIL (NASDAQ: GRAL).
Profile
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021, GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023, EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.
Joshua Ofman is CEO. Wikipedia
About Grail Inc
CEO-
Employees910
Founded2015
HeadquartersMenlo Park, California, United States
SectorBiotechnology
Websitegrail.com